RecruitingPhase 3NCT06859788
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Open-Label Study of SPI-1005 for the Treatment of Meniere's Disease
Sponsor
Sound Pharmaceuticals, Incorporated
Enrollment
200 participants
Start Date
Oct 29, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria7
- Adult males/females, 18-75 years of age at the time of enrollment.
- Diagnosis of probable or definite Meniere's Disease by AAO-HNS Amended 2015 Criteria.
- At least two of three active symptoms (fluctuating hearing; tinnitus; aural fullness; vertigo or dizziness) of Meniere's disease, within 3 months of study enrollment.
- Type A tympanogram at screening.
- Air conduction thresholds ≤ 90 dB at all tested frequencies (250-8000 Hz) in both ears.
- Subject is willing and able to provide informed consent and perform study procedures and assessments per protocol.
- Reproductive requirements
Exclusion Criteria11
- Current, or within 60 days prior to study enrollment, use of IV or intratympanic ototoxic medications such as chemotherapy including cisplatin, carboplatin, or oxaliplatin; aminoglycoside antibiotics including gentamicin, amikacin, tobramycin, kanamycin, or streptomycin; or loop diuretics including furosemide.
- History of otosclerosis or vestibular schwannoma.
- History of significant middle ear or inner ear surgery in the affected ear.
- Conductive hearing loss with air-bone gap ≥15 dB, otitis media, or mixed hearing loss.
- Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, neurological, or psychiatric disease.
- Current use or within 30 days prior to study enrollment systemic steroids.
- Current use or within 7 days prior to study enrollment intratympanic steroids.
- Hypersensitivity or idiosyncratic reaction to compounds related to ebselen or excipients.
- Female patients who are pregnant or breastfeeding.
- Participation in another investigational drug or device study within 30 days prior to study consent.
- Participant resides more than 100 miles from the study site.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEbselen
Glutathione peroxidase mimetic
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06859788